ID   SYVN1_HUMAN             Reviewed;         617 AA.
AC   Q86TM6; Q8N3K3; Q8N6E8; Q96JL5; Q96PK3;
DT   20-MAR-2007, integrated into UniProtKB/Swiss-Prot.
DT   20-MAR-2007, sequence version 2.
DT   28-JAN-2026, entry version 191.
DE   RecName: Full=E3 ubiquitin-protein ligase synoviolin;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:12646171, ECO:0000269|PubMed:12975321, ECO:0000269|PubMed:14593114, ECO:0000269|PubMed:17059562, ECO:0000269|PubMed:17141218, ECO:0000269|PubMed:17170702};
DE   AltName: Full=RING-type E3 ubiquitin transferase synoviolin {ECO:0000303|PubMed:12975321};
DE   AltName: Full=Synovial apoptosis inhibitor 1;
GN   Name=SYVN1 {ECO:0000303|PubMed:15489334};
GN   Synonyms=HRD1 {ECO:0000303|PubMed:12459480,
GN   ECO:0000303|PubMed:14593114, ECO:0000303|PubMed:15489334}, KIAA1810
GN   {ECO:0000303|PubMed:11347906, ECO:0000303|PubMed:15489334};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, MUTAGENESIS OF CYS-329, INDUCTION BY ER STRESS,
RP   AUTOUBIQUITINATION, AND PATHWAY.
RX   PubMed=12459480; DOI=10.1016/s0014-5793(02)03660-8;
RA   Kaneko M., Ishiguro M., Niinuma Y., Uesugi M., Nomura Y.;
RT   "Human HRD1 protects against ER stress-induced apoptosis through ER-
RT   associated degradation.";
RL   FEBS Lett. 532:147-152(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AUTOUBIQUITINATION, AND CATALYTIC ACTIVITY.
RX   PubMed=12646171; DOI=10.1016/s0006-291x(03)00279-1;
RA   Nadav E., Shmueli A., Barr H., Gonen H., Ciechanover A., Reiss Y.;
RT   "A novel mammalian endoplasmic reticulum ubiquitin ligase homologous to the
RT   yeast Hrd1.";
RL   Biochem. Biophys. Res. Commun. 303:91-97(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, TISSUE SPECIFICITY,
RP   AUTOUBIQUITINATION, AND CATALYTIC ACTIVITY.
RC   TISSUE=Articular cartilage;
RX   PubMed=12975321; DOI=10.1101/gad.1096603;
RA   Amano T., Yamasaki S., Yagishita N., Tsuchimochi K., Shin H., Kawahara K.,
RA   Aratani S., Fujita H., Zhang L., Ikeda R., Fujii R., Miura N., Komiya S.,
RA   Nishioka K., Maruyama I., Fukamizu A., Nakajima T.;
RT   "Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for
RT   arthropathy.";
RL   Genes Dev. 17:2436-2449(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, INDUCTION BY ER STRESS,
RP   LACK OF GLYCOSYLATION, SUBCELLULAR LOCATION, TOPOLOGY, AND CATALYTIC
RP   ACTIVITY.
RX   PubMed=14593114; DOI=10.1074/jbc.m307453200;
RA   Kikkert M., Doolman R., Dai M., Avner R., Hassink G., van Voorden S.,
RA   Thanedar S., Roitelman J., Chau V., Wiertz E.;
RT   "Human HRD1 is an E3 ubiquitin ligase involved in degradation of proteins
RT   from the endoplasmic reticulum.";
RL   J. Biol. Chem. 279:3525-3534(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RX   PubMed=11347906; DOI=10.1093/dnares/8.2.85;
RA   Nagase T., Nakayama M., Nakajima D., Kikuno R., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XX. The
RT   complete sequences of 100 new cDNA clones from brain which code for large
RT   proteins in vitro.";
RL   DNA Res. 8:85-95(2001).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Amygdala;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Blood;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   FUNCTION, HOMODIMERIZATION, INTERACTION WITH VCP; HERPUD1 AND DERL1,
RP   IDENTIFICATION IN A COMPLEX WITH HERPUD1; VIMP AND DERL1, AND PATHWAY.
RX   PubMed=16289116; DOI=10.1016/j.jmb.2005.10.020;
RA   Schulze A., Standera S., Buerger E., Kikkert M., van Voorden S., Wiertz E.,
RA   Koning F., Kloetzel P.-M., Seeger M.;
RT   "The ubiquitin-domain protein HERP forms a complex with components of the
RT   endoplasmic reticulum associated degradation pathway.";
RL   J. Mol. Biol. 354:1021-1027(2005).
RN   [9]
RP   INTERACTION WITH VCP, AND SUBCELLULAR LOCATION.
RX   PubMed=16186510; DOI=10.1073/pnas.0505006102;
RA   Ye Y., Shibata Y., Kikkert M., van Voorden S., Wiertz E., Rapoport T.A.;
RT   "Recruitment of the p97 ATPase and ubiquitin ligases to the site of
RT   retrotranslocation at the endoplasmic reticulum membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14132-14138(2005).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH DERL2 AND SEL1L, AND INTERACTION WITH
RP   SEL1L.
RX   PubMed=16186509; DOI=10.1073/pnas.0505014102;
RA   Lilley B.N., Ploegh H.L.;
RT   "Multiprotein complexes that link dislocation, ubiquitination, and
RT   extraction of misfolded proteins from the endoplasmic reticulum membrane.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:14296-14301(2005).
RN   [11]
RP   FUNCTION, PATHWAY, AND CATALYTIC ACTIVITY.
RX   PubMed=17059562; DOI=10.1111/j.1471-4159.2006.04155.x;
RA   Omura T., Kaneko M., Okuma Y., Orba Y., Nagashima K., Takahashi R.,
RA   Fujitani N., Matsumura S., Hata A., Kubota K., Murahashi K., Uehara T.,
RA   Nomura Y.;
RT   "A ubiquitin ligase HRD1 promotes the degradation of Pael receptor, a
RT   substrate of Parkin.";
RL   J. Neurochem. 99:1456-1469(2006).
RN   [12]
RP   FUNCTION, AND PATHWAY.
RX   PubMed=16847254; DOI=10.1073/pnas.0604816103;
RA   Arteaga M.F., Wang L., Ravid T., Hochstrasser M., Canessa C.M.;
RT   "An amphipathic helix targets serum and glucocorticoid-induced kinase 1 to
RT   the endoplasmic reticulum-associated ubiquitin-conjugation machinery.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:11178-11183(2006).
RN   [13]
RP   FUNCTION, INTERACTION WITH TP53, AND CATALYTIC ACTIVITY.
RX   PubMed=17170702; DOI=10.1038/sj.emboj.7601490;
RA   Yamasaki S., Yagishita N., Sasaki T., Nakazawa M., Kato Y., Yamadera T.,
RA   Bae E., Toriyama S., Ikeda R., Zhang L., Fujitani K., Yoo E.,
RA   Tsuchimochi K., Ohta T., Araya N., Fujita H., Aratani S., Eguchi K.,
RA   Komiya S., Maruyama I., Higashi N., Sato M., Senoo H., Ochi T.,
RA   Yokoyama S., Amano T., Kim J., Gay S., Fukamizu A., Nishioka K., Tanaka K.,
RA   Nakajima T.;
RT   "Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident
RT   ubiquitin ligase 'Synoviolin'.";
RL   EMBO J. 26:113-122(2007).
RN   [14]
RP   FUNCTION, INTERACTION WITH HTT, AND CATALYTIC ACTIVITY.
RX   PubMed=17141218; DOI=10.1016/j.yexcr.2006.10.031;
RA   Yang H., Zhong X., Ballar P., Luo S., Shen Y., Rubinsztein D.C.,
RA   Monteiro M.J., Fang S.;
RT   "Ubiquitin ligase Hrd1 enhances the degradation and suppresses the toxicity
RT   of polyglutamine-expanded huntingtin.";
RL   Exp. Cell Res. 313:538-550(2007).
RN   [15]
RP   INTERACTION WITH UBXN6.
RX   PubMed=18656546; DOI=10.1016/j.biocel.2008.06.008;
RA   Madsen L., Andersen K.M., Prag S., Moos T., Semple C.A., Seeger M.,
RA   Hartmann-Petersen R.;
RT   "Ubxd1 is a novel co-factor of the human p97 ATPase.";
RL   Int. J. Biochem. Cell Biol. 40:2927-2942(2008).
RN   [16]
RP   INTERACTION WITH ERLEC1; HSPA5; OS9 AND SEL1L.
RX   PubMed=18502753; DOI=10.1074/jbc.m709336200;
RA   Hosokawa N., Wada I., Nagasawa K., Moriyama T., Okawa K., Nagata K.;
RT   "Human XTP3-B forms an endoplasmic reticulum quality control scaffold with
RT   the HRD1-SEL1L ubiquitin ligase complex and BiP.";
RL   J. Biol. Chem. 283:20914-20924(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-613, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [18]
RP   INTERACTION WITH ERLEC1; OS9 AND SEL1L.
RX   PubMed=18264092; DOI=10.1038/ncb1689;
RA   Christianson J.C., Shaler T.A., Tyler R.E., Kopito R.R.;
RT   "OS-9 and GRP94 deliver mutant alpha1-antitrypsin to the Hrd1-SEL1L
RT   ubiquitin ligase complex for ERAD.";
RL   Nat. Cell Biol. 10:272-282(2008).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-613, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   INTERACTION WITH BAG6.
RX   PubMed=21636303; DOI=10.1016/j.molcel.2011.05.010;
RA   Wang Q., Liu Y., Soetandyo N., Baek K., Hegde R., Ye Y.;
RT   "A ubiquitin ligase-associated chaperone holdase maintains polypeptides in
RT   soluble states for proteasome degradation.";
RL   Mol. Cell 42:758-770(2011).
RN   [23]
RP   FUNCTION IN ERAD PATHWAY, AND PATHWAY.
RX   PubMed=22607976; DOI=10.1016/j.molcel.2012.04.015;
RA   Sato T., Sako Y., Sho M., Momohara M., Suico M.A., Shuto T., Nishitoh H.,
RA   Okiyoneda T., Kokame K., Kaneko M., Taura M., Miyata M., Chosa K., Koga T.,
RA   Morino-Koga S., Wada I., Kai H.;
RT   "STT3B-dependent posttranslational N-glycosylation as a surveillance system
RT   for secretory protein.";
RL   Mol. Cell 47:99-110(2012).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-613, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [26]
RP   FUNCTION, DEUBIQUITINATED BY USP19, AND MUTAGENESIS OF CYS-315.
RX   PubMed=27827840; DOI=10.3390/ijms17111829;
RA   Harada K., Kato M., Nakamura N.;
RT   "USP19-Mediated Deubiquitination Facilitates the Stabilization of HRD1
RT   Ubiquitin Ligase.";
RL   Int. J. Mol. Sci. 17:0-0(2016).
RN   [27]
RP   FUNCTION, INTERACTION WITH SEL1L, SUBCELLULAR LOCATION, AND PATHWAY.
RX   PubMed=26471130; DOI=10.1111/febs.13564;
RA   Hosokawa N., Wada I.;
RT   "Association of the SEL1L protein transmembrane domain with HRD1 ubiquitin
RT   ligase regulates ERAD-L.";
RL   FEBS J. 283:157-172(2016).
RN   [28]
RP   FUNCTION, IDENTIFICATION IN THE HRD1 COMPLEX, AND MUTAGENESIS OF CYS-294
RP   AND ARG-503.
RX   PubMed=28827405; DOI=10.1242/jcs.206847;
RA   Schulz J., Avci D., Queisser M.A., Gutschmidt A., Dreher L.S., Fenech E.J.,
RA   Volkmar N., Hayashi Y., Hoppe T., Christianson J.C.;
RT   "Conserved cytoplasmic domains promote Hrd1 ubiquitin ligase complex
RT   formation for ER-associated degradation (ERAD).";
RL   J. Cell Sci. 130:3322-3335(2017).
RN   [29]
RP   FUNCTION, AND INVOLVEMENT IN ABC-DLBCL.
RX   PubMed=28842558; DOI=10.1038/s41467-017-00476-w;
RA   Wang W.F., Yan L., Liu Z., Liu L.X., Lin J., Liu Z.Y., Chen X.P., Zhang W.,
RA   Xu Z.Z., Shi T., Li J.M., Zhao Y.L., Meng G., Xia Y., Li J.Y., Zhu J.;
RT   "HSP70-Hrd1 axis precludes the oncorepressor potential of N-terminal
RT   misfolded Blimp-1s in lymphoma cells.";
RL   Nat. Commun. 8:363-363(2017).
RN   [30]
RP   VARIANT LEU-398, CHARACTERIZATION OF VARIANT LEU-398, AND INTERACTION WITH
RP   SEL1L.
RX   PubMed=37943610; DOI=10.1172/jci170054;
RA   Wang H.H., Lin L.L., Li Z.J., Wei X., Askander O., Cappuccio G.,
RA   Hashem M.O., Hubert L., Munnich A., Alqahtani M., Pang Q., Burmeister M.,
RA   Lu Y., Poirier K., Besmond C., Sun S., Brunetti-Pierri N., Alkuraya F.S.,
RA   Qi L.;
RT   "Hypomorphic variants of SEL1L-HRD1 ER-associated degradation are
RT   associated with neurodevelopmental disorders.";
RL   J. Clin. Invest. 134:0-0(2024).
RN   [31] {ECO:0007744|PDB:6A3Z}
RP   STRUCTURE BY NMR OF 279-334 IN COMPLEX WITH ZINC.
RX   PubMed=30345569; DOI=10.1002/pro.3532;
RA   Miyamoto K., Taguchi Y., Saito K.;
RT   "Unique RING finger structure from the human HRD1 protein.";
RL   Protein Sci. 28:448-453(2019).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin
CC       specifically from endoplasmic reticulum-associated UBC7 E2 ligase and
CC       transfers it to substrates, promoting their degradation
CC       (PubMed:12459480, PubMed:12646171, PubMed:12975321, PubMed:14593114,
CC       PubMed:16289116, PubMed:16847254, PubMed:17059562, PubMed:17141218,
CC       PubMed:17170702, PubMed:22607976, PubMed:27827840, PubMed:26471130,
CC       PubMed:28827405). Component of the endoplasmic reticulum quality
CC       control (ERQC) system also called ER-associated degradation (ERAD)
CC       involved in ubiquitin-dependent degradation of misfolded endoplasmic
CC       reticulum proteins (PubMed:12459480, PubMed:12646171, PubMed:12975321,
CC       PubMed:14593114, PubMed:16289116, PubMed:16847254, PubMed:17059562,
CC       PubMed:17141218, PubMed:17170702, PubMed:22607976, PubMed:26471130,
CC       PubMed:28842558). Also promotes the degradation of normal but naturally
CC       short-lived proteins such as SGK. Protects cells from ER stress-induced
CC       apoptosis. Protects neurons from apoptosis induced by polyglutamine-
CC       expanded huntingtin (HTT) or unfolded GPR37 by promoting their
CC       degradation (PubMed:17141218). Sequesters p53/TP53 in the cytoplasm and
CC       promotes its degradation, thereby negatively regulating its biological
CC       function in transcription, cell cycle regulation and apoptosis
CC       (PubMed:17170702). Mediates the ubiquitination and subsequent
CC       degradation of cytoplasmic NFE2L1 (By similarity). During the early
CC       stage of B cell development, required for degradation of the pre-B cell
CC       receptor (pre-BCR) complex, hence supporting further differentiation
CC       into mature B cells (By similarity). {ECO:0000250|UniProtKB:Q9DBY1,
CC       ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:12646171,
CC       ECO:0000269|PubMed:12975321, ECO:0000269|PubMed:14593114,
CC       ECO:0000269|PubMed:16289116, ECO:0000269|PubMed:16847254,
CC       ECO:0000269|PubMed:17059562, ECO:0000269|PubMed:17141218,
CC       ECO:0000269|PubMed:17170702, ECO:0000269|PubMed:22607976,
CC       ECO:0000269|PubMed:26471130, ECO:0000269|PubMed:27827840,
CC       ECO:0000269|PubMed:28827405, ECO:0000269|PubMed:28842558}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:12646171,
CC         ECO:0000269|PubMed:12975321, ECO:0000269|PubMed:14593114,
CC         ECO:0000269|PubMed:17059562, ECO:0000269|PubMed:17141218,
CC         ECO:0000269|PubMed:17170702};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:16289116,
CC       ECO:0000269|PubMed:16847254, ECO:0000269|PubMed:17059562,
CC       ECO:0000269|PubMed:22607976, ECO:0000269|PubMed:26471130}.
CC   -!- SUBUNIT: Homodimer (PubMed:16289116). Interacts with p53/TP53
CC       (PubMed:17170702). Interacts with HTT (PubMed:17141218). Component of
CC       the HRD1 complex, which comprises at least SYNV1/HRD1, DERL1/2, FAM8A1,
CC       HERPUD1/HERP, OS9, SEL1L and UBE2J1 (PubMed:16186509, PubMed:16289116,
CC       PubMed:18264092, PubMed:26471130, PubMed:28827405, PubMed:37943610).
CC       FAM8A1 is stabilized by interaction with SYNV1, which prevents its
CC       proteasomal degradation. OS9 and UBE2J1 recruitment to the complex may
CC       be mediated by SEL1L (PubMed:28827405). SYNV1 assembles with SEL1L and
CC       FAM8A1 through its transmembrane domains, but interaction with its
CC       cytoplasmic domain is required to confer stability to FAM8A1 and
CC       enhance recruitment of HERPUD1 (PubMed:28827405). The HRD1 complex also
CC       associates with VIMP and may transfer misfolded proteins from the
CC       endoplasmic reticulum to VCP (PubMed:16289116). May form a complex with
CC       ERLEC1, HSPA5, OS9 and SEL1L (PubMed:18264092, PubMed:18502753).
CC       Interacts with VCP (PubMed:16186510, PubMed:16289116). Interacts with
CC       UBXN6 (PubMed:18656546). Interacts with BAG6 (PubMed:21636303).
CC       Interacts with NFE2L1 (By similarity). Interacts (via N-terminus) with
CC       components of the pre-B cell receptor, including IGLL1 and VPREB1 (By
CC       similarity). Interacts with CREB3L3; this interaction leads to CREB3L3
CC       ubiquitination and proteasomal degradation (By similarity).
CC       {ECO:0000250|UniProtKB:Q9DBY1, ECO:0000269|PubMed:16186509,
CC       ECO:0000269|PubMed:16186510, ECO:0000269|PubMed:16289116,
CC       ECO:0000269|PubMed:17141218, ECO:0000269|PubMed:17170702,
CC       ECO:0000269|PubMed:18264092, ECO:0000269|PubMed:18502753,
CC       ECO:0000269|PubMed:18656546, ECO:0000269|PubMed:21636303,
CC       ECO:0000269|PubMed:26471130, ECO:0000269|PubMed:28827405,
CC       ECO:0000269|PubMed:37943610}.
CC   -!- INTERACTION:
CC       Q86TM6; O75477: ERLIN1; NbExp=2; IntAct=EBI-947849, EBI-359299;
CC       Q86TM6; O94905: ERLIN2; NbExp=2; IntAct=EBI-947849, EBI-4400770;
CC       Q86TM6; O75460: ERN1; NbExp=2; IntAct=EBI-947849, EBI-371750;
CC       Q86TM6; O75460-1: ERN1; NbExp=3; IntAct=EBI-947849, EBI-15600828;
CC       Q86TM6; Q9UBU6: FAM8A1; NbExp=22; IntAct=EBI-947849, EBI-6309101;
CC       Q86TM6; Q9UBV2: SEL1L; NbExp=21; IntAct=EBI-947849, EBI-358766;
CC       Q86TM6; P04637: TP53; NbExp=5; IntAct=EBI-947849, EBI-366083;
CC       Q86TM6; Q9Y385: UBE2J1; NbExp=15; IntAct=EBI-947849, EBI-988826;
CC       Q86TM6; Q9Y4E8: USP15; NbExp=8; IntAct=EBI-947849, EBI-1043104;
CC   -!- SUBCELLULAR LOCATION: Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:12646171,
CC       ECO:0000269|PubMed:14593114, ECO:0000269|PubMed:16186510,
CC       ECO:0000269|PubMed:26471130}; Multi-pass membrane protein
CC       {ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:12646171,
CC       ECO:0000269|PubMed:14593114, ECO:0000269|PubMed:16186510}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=b, long;
CC         IsoId=Q86TM6-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q86TM6-2; Sequence=VSP_023777, VSP_023778;
CC       Name=3; Synonyms=a, short;
CC         IsoId=Q86TM6-3; Sequence=VSP_023778;
CC   -!- TISSUE SPECIFICITY: Ubiquitously expressed, with highest levels in
CC       liver and kidney (at protein level). Up-regulated in synovial tissues
CC       from patients with rheumatoid arthritis (at protein level).
CC       {ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:12646171,
CC       ECO:0000269|PubMed:12975321}.
CC   -!- INDUCTION: By endoplasmic reticulum stress-inducing agents such as
CC       thapsigargin, tunicamycin or brefeldin A, but not by heat shock.
CC       {ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:14593114}.
CC   -!- DOMAIN: The RING-type zinc finger is required for E3 ligase activity.
CC   -!- PTM: Not N-glycosylated.
CC   -!- PTM: Auto-ubiquitinated. Deubiquitinated by USP19 (PubMed:27827840).
CC       {ECO:0000269|PubMed:12459480, ECO:0000269|PubMed:12646171,
CC       ECO:0000269|PubMed:12975321, ECO:0000269|PubMed:27827840}.
CC   -!- DISEASE: Note=In certain aggressive cases of activated B cell-like
CC       diffuse large B-cell lymphoma (ABC-DLBCL), plays a role in the
CC       degradation of misfolded N-terminal mutated PRDM1 proteins.
CC       {ECO:0000269|PubMed:28842558}.
CC   -!- SIMILARITY: Belongs to the HRD1 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB47439.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB085847; BAC24801.1; -; mRNA.
DR   EMBL; AB024690; BAC57449.1; -; mRNA.
DR   EMBL; AF317634; AAL26903.1; -; mRNA.
DR   EMBL; AB058713; BAB47439.1; ALT_INIT; mRNA.
DR   EMBL; AL834262; CAD38937.1; -; mRNA.
DR   EMBL; BC030530; AAH30530.1; -; mRNA.
DR   CCDS; CCDS31605.1; -. [Q86TM6-1]
DR   CCDS; CCDS8097.1; -. [Q86TM6-3]
DR   RefSeq; NP_115807.1; NM_032431.3. [Q86TM6-3]
DR   RefSeq; NP_757385.1; NM_172230.3. [Q86TM6-1]
DR   RefSeq; XP_011543605.1; XM_011545303.4. [Q86TM6-1]
DR   RefSeq; XP_047283669.1; XM_047427713.1. [Q86TM6-3]
DR   RefSeq; XP_054226167.1; XM_054370192.1. [Q86TM6-1]
DR   RefSeq; XP_054226168.1; XM_054370193.1. [Q86TM6-3]
DR   PDB; 6A3Z; NMR; -; A=279-334.
DR   PDB; 8KES; EM; 3.50 A; A/B=1-617.
DR   PDB; 8KET; EM; 3.30 A; A/B=1-617.
DR   PDB; 8KEV; EM; 3.50 A; A/B=1-617.
DR   PDB; 9OG0; EM; 3.64 A; A/B=1-617.
DR   PDBsum; 6A3Z; -.
DR   PDBsum; 8KES; -.
DR   PDBsum; 8KET; -.
DR   PDBsum; 8KEV; -.
DR   PDBsum; 9OG0; -.
DR   AlphaFoldDB; Q86TM6; -.
DR   EMDB; EMD-37166; -.
DR   EMDB; EMD-37167; -.
DR   EMDB; EMD-37168; -.
DR   EMDB; EMD-63459; -.
DR   EMDB; EMD-63996; -.
DR   EMDB; EMD-70448; -.
DR   SMR; Q86TM6; -.
DR   BioGRID; 124085; 382.
DR   CORUM; Q86TM6; -.
DR   DIP; DIP-43982N; -.
DR   FunCoup; Q86TM6; 2164.
DR   IntAct; Q86TM6; 127.
DR   MINT; Q86TM6; -.
DR   STRING; 9606.ENSP00000366395; -.
DR   TCDB; 3.A.16.1.4; the endoplasmic reticular retrotranslocon (er-rt) family.
DR   GlyGen; Q86TM6; 6 sites, 1 O-linked glycan (4 sites).
DR   iPTMnet; Q86TM6; -.
DR   PhosphoSitePlus; Q86TM6; -.
DR   SwissPalm; Q86TM6; -.
DR   BioMuta; SYVN1; -.
DR   DMDM; 134035039; -.
DR   jPOST; Q86TM6; -.
DR   MassIVE; Q86TM6; -.
DR   PaxDb; 9606-ENSP00000366395; -.
DR   PeptideAtlas; Q86TM6; -.
DR   ProteomicsDB; 69713; -. [Q86TM6-1]
DR   ProteomicsDB; 69714; -. [Q86TM6-2]
DR   ProteomicsDB; 69715; -. [Q86TM6-3]
DR   Pumba; Q86TM6; -.
DR   Antibodypedia; 1694; 390 antibodies from 36 providers.
DR   DNASU; 84447; -.
DR   Ensembl; ENST00000294256.12; ENSP00000294256.8; ENSG00000162298.20. [Q86TM6-3]
DR   Ensembl; ENST00000307289.10; ENSP00000302035.6; ENSG00000162298.20. [Q86TM6-2]
DR   Ensembl; ENST00000377190.8; ENSP00000366395.3; ENSG00000162298.20. [Q86TM6-1]
DR   Ensembl; ENST00000526060.5; ENSP00000436984.1; ENSG00000162298.20. [Q86TM6-3]
DR   GeneID; 84447; -.
DR   KEGG; hsa:84447; -.
DR   MANE-Select; ENST00000377190.8; ENSP00000366395.3; NM_172230.3; NP_757385.1.
DR   UCSC; uc001odb.4; human. [Q86TM6-1]
DR   AGR; HGNC:20738; -.
DR   ClinPGx; PA128394735; -.
DR   CTD; 84447; -.
DR   DisGeNET; 84447; -.
DR   GeneCards; SYVN1; -.
DR   HGNC; HGNC:20738; SYVN1.
DR   HPA; ENSG00000162298; Low tissue specificity.
DR   MIM; 608046; gene.
DR   OpenTargets; ENSG00000162298; -.
DR   VEuPathDB; HostDB:ENSG00000162298; -.
DR   eggNOG; KOG0802; Eukaryota.
DR   GeneTree; ENSGT00940000157743; -.
DR   HOGENOM; CLU_009169_3_0_1; -.
DR   InParanoid; Q86TM6; -.
DR   OMA; PGMGAPF; -.
DR   OrthoDB; 7759664at2759; -.
DR   PAN-GO; Q86TM6; 3 GO annotations based on evolutionary models.
DR   PhylomeDB; Q86TM6; -.
DR   PathwayCommons; Q86TM6; -.
DR   Reactome; R-HSA-381038; XBP1(S) activates chaperone genes.
DR   Reactome; R-HSA-5358346; Hedgehog ligand biogenesis.
DR   Reactome; R-HSA-5362768; Hh mutants are degraded by ERAD.
DR   Reactome; R-HSA-901032; ER Quality Control Compartment (ERQC).
DR   SignaLink; Q86TM6; -.
DR   SIGNOR; Q86TM6; -.
DR   UniPathway; UPA00143; -.
DR   Agora; ENSG00000162298; -.
DR   BioGRID-ORCS; 84447; 239 hits in 1216 CRISPR screens.
DR   ChiTaRS; SYVN1; human.
DR   GeneWiki; SYVN1; -.
DR   GenomeRNAi; 84447; -.
DR   Pharos; Q86TM6; Tbio.
DR   PRO; PR:Q86TM6; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; Q86TM6; protein.
DR   Bgee; ENSG00000162298; Expressed in ileal mucosa and 178 other cell types or tissues.
DR   ExpressionAtlas; Q86TM6; baseline and differential.
DR   GO; GO:0036513; C:Derlin-1 retrotranslocation complex; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0012505; C:endomembrane system; IBA:GO_Central.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0044322; C:endoplasmic reticulum quality control compartment; IDA:UniProtKB.
DR   GO; GO:0000836; C:Hrd1p ubiquitin ligase complex; IDA:UniProtKB.
DR   GO; GO:0000839; C:Hrd1p ubiquitin ligase ERAD-L complex; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005790; C:smooth endoplasmic reticulum; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0051117; F:ATPase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0140297; F:DNA-binding transcription factor binding; IEA:Ensembl.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:1990381; F:ubiquitin-specific protease binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0051082; F:unfolded protein binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:UniProtKB-KW.
DR   GO; GO:1904380; P:endoplasmic reticulum mannose trimming; TAS:Reactome.
DR   GO; GO:0036503; P:ERAD pathway; IDA:UniProtKB.
DR   GO; GO:0002327; P:immature B cell differentiation; ISS:UniProtKB.
DR   GO; GO:1902236; P:negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IBA:GO_Central.
DR   GO; GO:0070936; P:protein K48-linked ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0050821; P:protein stabilization; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0030970; P:retrograde protein transport, ER to cytosol; IMP:ParkinsonsUK-UCL.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IDA:ParkinsonsUK-UCL.
DR   CDD; cd16479; RING-H2_synoviolin; 1.
DR   FunFam; 3.30.40.10:FF:000088; E3 ubiquitin-protein ligase synoviolin; 1.
DR   Gene3D; 3.30.40.10; Zinc/RING finger domain, C3HC4 (zinc finger); 1.
DR   InterPro; IPR050731; HRD1_E3_ubiq-ligases.
DR   InterPro; IPR057992; TPR_SYVN1_N.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR058051; Znf_RING_synoviolin.
DR   PANTHER; PTHR22763:SF184; E3 UBIQUITIN-PROTEIN LIGASE SYNOVIOLIN; 1.
DR   PANTHER; PTHR22763; RING ZINC FINGER PROTEIN; 1.
DR   Pfam; PF25563; TPR_SYVN1_N; 1.
DR   Pfam; PF13639; zf-RING_2; 1.
DR   PRINTS; PR01217; PRICHEXTENSN.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF57850; RING/U-box; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Endoplasmic reticulum; Membrane;
KW   Metal-binding; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Stress response; Transferase; Transmembrane;
KW   Transmembrane helix; Ubl conjugation; Ubl conjugation pathway; Zinc;
KW   Zinc-finger.
FT   CHAIN           1..617
FT                   /note="E3 ubiquitin-protein ligase synoviolin"
FT                   /id="PRO_0000280548"
FT   TOPO_DOM        1..4
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        5..25
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        26..41
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        42..62
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        63..98
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        99..119
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        120..140
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        141..161
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        162..169
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        170..190
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        191..224
FT                   /note="Lumenal"
FT                   /evidence="ECO:0000305"
FT   TRANSMEM        225..245
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        246..617
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000305"
FT   ZN_FING         291..330
FT                   /note="RING-type; atypical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   REGION          1..251
FT                   /note="Involved in FAM8A1 interaction"
FT                   /evidence="ECO:0000269|PubMed:28827405"
FT   REGION          1..84
FT                   /note="Necessary and sufficient for SEL1L interaction"
FT                   /evidence="ECO:0000269|PubMed:28827405"
FT   REGION          236..270
FT                   /note="Interaction with p53/TP53"
FT                   /evidence="ECO:0000269|PubMed:17170702"
FT   REGION          337..375
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          393..453
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          480..535
FT                   /note="HAF-H domain; necessary to form higher-order Hrd1
FT                   complexes"
FT                   /evidence="ECO:0000303|PubMed:28827405"
FT   REGION          535..617
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        341..375
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        417..451
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        537..569
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        591..600
FT                   /note="Acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         291
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         294
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         307
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         309
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         312
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         315
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         326
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   BINDING         329
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000269|PubMed:30345569,
FT                   ECO:0007744|PDB:6A3Z"
FT   MOD_RES         613
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         127..177
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:11347906"
FT                   /id="VSP_023777"
FT   VAR_SEQ         411
FT                   /note="Missing (in isoform 2 and isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11347906,
FT                   ECO:0000303|PubMed:12459480, ECO:0000303|PubMed:14593114,
FT                   ECO:0000303|PubMed:17974005"
FT                   /id="VSP_023778"
FT   VARIANT         398
FT                   /note="P -> L (found in a patient with a neurodevelopmental
FT                   disorder; uncertain significance; results in decreased
FT                   protein ubiquitination of misfolded substrates and impaired
FT                   ER-associated protein degradation; dbSNP:rs370870880)"
FT                   /evidence="ECO:0000269|PubMed:37943610"
FT                   /id="VAR_090404"
FT   MUTAGEN         294
FT                   /note="C->A: No effect on interaction with FAM8A1, HERPUD1,
FT                   OS9, SEL1L and UBE2J1."
FT                   /evidence="ECO:0000269|PubMed:28827405"
FT   MUTAGEN         315
FT                   /note="C->S: Decreased 'Lys-48'-linked ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:27827840"
FT   MUTAGEN         329
FT                   /note="C->S: Abolishes E3 ligase activity."
FT                   /evidence="ECO:0000269|PubMed:12459480"
FT   MUTAGEN         503
FT                   /note="R->L: Loss of interaction with FAM8A1, HERPUD1, OS9
FT                   and UBE2J1, impaired degradation of immature
FT                   core-glycosylated basigin/CD147."
FT                   /evidence="ECO:0000269|PubMed:28827405"
FT   CONFLICT        145
FT                   /note="M -> I (in Ref. 1; BAC24801 and 4; AAL26903)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        545
FT                   /note="E -> G (in Ref. 3; BAC57449)"
FT                   /evidence="ECO:0000305"
FT   HELIX           2..25
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           29..38
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           40..65
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   STRAND          66..68
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           73..95
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           101..129
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           135..165
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           170..199
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           206..236
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   STRAND          237..239
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   STRAND          242..244
FT                   /evidence="ECO:0007829|PDB:8KES"
FT   HELIX           246..265
FT                   /evidence="ECO:0007829|PDB:8KET"
FT   HELIX           281..285
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   TURN            286..289
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   TURN            292..295
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   STRAND          299..304
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   STRAND          310..312
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   HELIX           313..319
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   TURN            320..322
FT                   /evidence="ECO:0007829|PDB:6A3Z"
FT   TURN            327..329
FT                   /evidence="ECO:0007829|PDB:6A3Z"
SQ   SEQUENCE   617 AA;  67685 MW;  B8A6BACBAF9673C1 CRC64;
     MFRTAVMMAA SLALTGAVVA HAYYLKHQFY PTVVYLTKSS PSMAVLYIQA FVLVFLLGKV
     MGKVFFGQLR AAEMEHLLER SWYAVTETCL AFTVFRDDFS PRFVALFTLL LFLKCFHWLA
     EDRVDFMERS PNISWLFHCR IVSLMFLLGI LDFLFVSHAY HSILTRGASV QLVFGFEYAI
     LMTMVLTIFI KYVLHSVDLQ SENPWDNKAV YMLYTELFTG FIKVLLYMAF MTIMIKVHTF
     PLFAIRPMYL AMRQFKKAVT DAIMSRRAIR NMNTLYPDAT PEELQAMDNV CIICREEMVT
     GAKRLPCNHI FHTSCLRSWF QRQQTCPTCR MDVLRASLPA QSPPPPEPAD QGPPPAPHPP
     PLLPQPPNFP QGLLPPFPPG MFPLWPPMGP FPPVPPPPSS GEAVAPPSTS AAALSRPSGA
     ATTTAAGTSA TAASATASGP GSGSAPEAGP APGFPFPPPW MGMPLPPPFA FPPMPVPPAG
     FAGLTPEELR ALEGHERQHL EARLQSLRNI HTLLDAAMLQ INQYLTVLAS LGPPRPATSV
     NSTEETATTV VAAASSTSIP SSEATTPTPG ASPPAPEMER PPAPESVGTE EMPEDGEPDA
     AELRRRRLQK LESPVAH
//
